Table 2.

Cox regression and Fine-Gray competing risk regression analysis of non-neoplastic and neoplastic mortality risk over 22 years of follow-up after ACS with the interaction for risks between the six geographic areas (n = 541).

Variable	Unadjusted			Fully adjusted*
	HR (95% CI)	Z	p	HR (95% CI)	Z	p
Cox regression
Non-neoplastic mortality (n = 321)
urban-rural areas	0.8 (0.7–1.0)	-1.8	0.08	0.9 (0.7–1.1)	-1.2	0.24
southern-northern provinces	1.1 (1.0–1.3)	1.6	0.10	1.0 (0.8–1.1)	-0.4	0.71
Interaction (urban/rural areas and south to north provinces)	1.0 (0.7–1.2)	-0.3	0.74	1.1 (0.9–1.4)	0.8	0.41
Neoplastic mortality (n = 99)
urban-rural areas	1.1 (0.7–1.7)	0.5	0.59	1.3 (0.8–1.9)	1.1	0.27
southern-northern provinces	1.1 (0.9–1.4)	1.1	0.29	1.0 (0.8–1.3)	0.3	0.74
Interaction (urban/rural areas and south to north provinces)	1.9 (1.1–3.0)	2.4	0.01	2.1 (1.3–3.4)	2.9	0.003
Fine-Gray competing risk regression analysis
	SHR (95% CI)	Z	p	SHR (95% CI)	Z	p
Non-neoplastic mortality (n = 321)
urban-rural areas	0.8 (0.7–1.0)	-1.8	0.07	0.8 (0.7–1.1)	-1.4	0.17
southern-northern provinces	1.1 (1.0–1.2)	1.2	0.25	1.0 (0.8–1.1)	-0.2	0.82
Interaction (urban/rural areas and south to north provinces)	0.9 (0.7–1.1)	-0.9	0.38	0.9 (0.7–1.2)	-0.5	0.60
Neoplastic mortality (n = 99)
urban-rural areas	1.2 (0.8–1.8)	0.9	0.32	1.3 (0.8–1.9)	1.2	0.25
southern-northern provinces	1.1 (0.8–1.3)	0.5	0.60	1.1 (0.9–1.4)	0.8	0.45
Interaction (urban/rural areas and south to north provinces)	1.8 (1.1–3.0)	2.4	0.01	1.9 (1.1–3.0)	2.6	0.01

CI, confidence interval; HR, hazard ratio; SHR, sub-hazard ratio.

P-values were calculated for log-transformed data. *Adjusted for age, sex, smoking, education level, alcohol consumption, baseline serum cholesterol, presence of heart failure at admission, and anti-platelet and beta-blockers time-intensity treatment per cent during follow-up.